

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/599,452	06/22/2000	Fredric R. Bloom	0942.4970001/RWE/BJD	7893	
26111	7590 07/29/2003				
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			EXAMINER		
			LAMBERTSON, DAVID A		
			ART UNIT	PAPER NUMBER	
			1636	23	
			DATE MAILED: 07/29/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/599,452	BLOOM ET AL.			
·	Examiner	Art Unit			
	David A. Lambertson	1636			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress		
THE REPLY FILED 02 July 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR RE	PLY [check either a) or b)]				
a) The period for reply expiresmonths from the mailing of b) The period for reply expires on: (1) the mailing date of this Adverse, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The dath have been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mo	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THE te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the statutory period for reply originally set in the statutory period for the stat	the final rejection.  FINAL REJECTION. S  36(a) and the appropriate ext fee. The appropriate ext the final Office action: or	See MPEP  e extension fee tension fee under (2) as set forth in		
earned patent term adjustment. See 37 CFR 1.704(b).	mane and the meaning date of the initial roje	caon, even ir amery med,	may reduce any		
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFI	s Brief must be filed within the p R 1.191(d)), to avoid dismissal o	eriod set forth in of the appeal.			
2. The proposed amendment(s) will not be entered be	ecause:				
(a)  they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) ☐ they raise the issue of new matter (see Note below);					
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejection	tion(s):				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	d amendment		
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for application in condition for allowance because: Se	r reconsideration has been cons e Continuation Sheet.	idered but does NC	OT place the		
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which we	re newly		
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	(s) a) $\boxtimes$ will not be entered or by build be rejected is provided below	will be entered w or appended.	and an		
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: <u>48-96 and 106-126</u> .					
Claim(s) objected to: 42,43,45-47,97,103-105 and 13	<u>80-138</u> .				
Claim(s) rejected: <u>139-149</u> .					
Claim(s) withdrawn from consideration:					
.☐ The proposed drawing correction filed on is a)☐ approved or b)☐ disapproved by the Examiner.					
$9. \boxtimes$ Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s). <u>2</u>	<u>1</u> .			
10. Other:	PRIMA	NB GUZO RY EXAMINER	-		
		<b>y</b>			

## Continuation Sheet (PTO-303) 009/599,452

Application No.

Continuation of 2. NOTE: the amendment to claims 42, 97 and 147 raises new issues regarding the indefiniteness of the claims because it is now unclear as to whether the claim is referring to a purified culture of cells or a mixed culture of cells by the indication of "One or more E. coli cells". Additionally, the claims as they now read encompass multiple embodiments that were not previously contemplated. This also raises new idefiniteness issues regarding the antecedent basis of the depending claims, as it would be unclear as to which E. coli strain in the potential mixed population was being referred to. As stated previously in the Final Action, it would be remedial to use an article (e.g., "A", "An" or "The") to begin the claim.

Continuation of 5. does NOT place the application in condition for allowance because: the statement regarding the deposit of biological material is unclear. Applicant has not clearly indicated which of the deposited strains will have their restrictions irrevocably removed upon the granting of the patent, and they have not specifically indicated which deposited strains are known and readily available to the public. In addition, applicant's amendment of claims 42, 97 and 147 to read "One or more E. coli cells" does not overcome the objection to the claims, and in fact raises new indefiniteness issues regarding whether the claim is supposed to read on a pure culture of cells or a mixed culture of cells, etc. The claim also encompasses multiple new embodiments that were not previously contemplated as a result of the new language.